DOI: 10.1136/gutjnl-2017-315766

,  

,  

PMID: 29331941

MEDLINE Status: Publisher

Issn Electronic: 1468-3288


Print

Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.

Célia Gouynou; Lieven Pouillon; Hélène Rousseau; Camille Zallot; Cédric Baumann; Laurent Peyrin-Biroulet

+ Author Information

Author Information: Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Clinical Research Support Facility PARC, UMDS Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Clinical Research Support Facility PARC, UMDS Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles